Sustained NF-kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus

被引:27
作者
Frenzel, Lukas P. [1 ,2 ]
Claus, Rainer [3 ]
Plume, Nadine [4 ,5 ]
Schwamb, Janine [1 ,2 ]
Konermann, Carolin [3 ]
Pallasch, Christian P. [1 ,2 ,6 ]
Claasen, Julia [1 ,2 ]
Brinker, Reinhild [1 ,2 ]
Wollnik, Bernd [4 ,5 ]
Plass, Christoph [3 ]
Wendtner, Clemens-Martin [1 ,2 ]
机构
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Cologne, CIO, Cologne, Germany
[3] German Canc Res Ctr, Div Epigenom & Canc Risk Factors, D-6900 Heidelberg, Germany
[4] Univ Cologne, Inst Human Genet, D-50937 Cologne, Germany
[5] Univ Cologne, CMMC, D-50937 Cologne, Germany
[6] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA
关键词
CLL; A20; TNFAIP3; methylation; NF-kappa B; B-CELL LYMPHOMA; CPG METHYLATION; MUTATIONS; OVEREXPRESSION; INHIBITION;
D O I
10.1002/ijc.25579
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inappropriate nuclear factor (NF) kappa B activity is one major hallmark of B-cell malignancies and chronic lymphocytic leukemia (CLL). NF kappa B-dependent genes are involved in antiapoptosis, cell proliferation and metastasis and are responsible for survival and proliferation of tumors. However, the mechanisms of NF kappa B activity in CLL still need to be elucidated. Previously, we identified translocations in a region on chromosome 6q that encodes tumor necrosis factor alpha-induced protein 3, which is a key player in negative feedback loop regulation of NF kappa B. Inactivation of this ubiquitin-editing enzyme is involved in immunopathologies and in tumorigenesis. Frequent mutations in the A20 locus-leading to sustained NF kappa B activity-could be shown to play a dominant role in development of different B-cell malignancies. To check if A20 is involved in upregulation of NF kappa B activity in CLL, we sequenced Exons 2-9 of the A20 gene in 55 CLL DNA samples. Furthermore, we determined the methylation status of the promoter region in 63 CLL DNA samples and compared to 10 control DNAs of B cells from healthy donors. Contrary to reports from other B-cell malignancies, the A20 region showed neither mutations nor aberrant DNA methylation. Moreover, its expression could be confirmed by immunoblotting and showing comparable results to healthy B cells. These results indicate that malignant development in CLL differs from most of other B-cell malignancies, which show frequent inactivation of A20.
引用
收藏
页码:2495 / 2500
页数:6
相关论文
共 25 条
[1]   Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia [J].
Binet, JL ;
Caligaris-Cappio, F ;
Catovsky, D ;
Cheson, B ;
Davis, T ;
Dighiero, G ;
Döhner, H ;
Hallek, M ;
Hillmen, P ;
Keating, M ;
Montserrat, E ;
Kipps, TJ ;
Rai, K .
BLOOD, 2006, 107 (03) :859-861
[2]   The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses [J].
Boone, DL ;
Turer, EE ;
Lee, EG ;
Ahmad, RC ;
Wheeler, MT ;
Tsui, C ;
Hurley, P ;
Chien, M ;
Chai, S ;
Hitotsumatsu, O ;
McNally, E ;
Pickart, C ;
Ma, A .
NATURE IMMUNOLOGY, 2004, 5 (10) :1052-1060
[3]   A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma [J].
Chanudet, E. ;
Huang, Y. ;
Ichimura, K. ;
Dong, G. ;
Hamoudi, R. A. ;
Radford, J. ;
Wotherspoon, A. C. ;
Isaacson, P. G. ;
Ferry, J. ;
Du, M-Q .
LEUKEMIA, 2010, 24 (02) :483-487
[4]   Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma [J].
Compagno, Mara ;
Lim, Wei Keat ;
Grunn, Adina ;
Nandula, Subhadra V. ;
Brahmachary, Manisha ;
Shen, Qiong ;
Bertoni, Francesco ;
Ponzoni, Maurilio ;
Scandurra, Marta ;
Califano, Andrea ;
Bhagat, Govind ;
Chadburn, Amy ;
Dalla-Favera, Riccardo ;
Pasqualucci, Laura .
NATURE, 2009, 459 (7247) :717-U124
[5]   A20: Central Gatekeeper in Inflammation and Immunity [J].
Coornaert, Beatrice ;
Carpentier, Isabelle ;
Beyaert, Rudi .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (13) :8217-8221
[6]   A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia [J].
Di Bernardo, Maria Chiara ;
Crowther-Swanepoel, Dalemari ;
Broderick, Peter ;
Webb, Emily ;
Sellick, Gabrielle ;
Wild, Ruth ;
Sullivan, Kate ;
Vijayakrishnan, Jayaram ;
Wang, Yufei ;
Pittman, Alan M. ;
Sunter, Nicola J. ;
Hall, Andrew G. ;
Dyer, Martin J. S. ;
Matutes, Estella ;
Dearden, Claire ;
Mainou-Fowler, Tryfonia ;
Jackson, Graham H. ;
Summerfield, Geoffrey ;
Harris, Robert J. ;
Pettitt, Andrew R. ;
Hillmen, Peter ;
Allsup, David J. ;
Bailey, James R. ;
Pratt, Guy ;
Pepper, Chris ;
Fegan, Chris ;
Allan, James M. ;
Catovsky, Daniel ;
Houlston, Richard S. .
NATURE GENETICS, 2008, 40 (10) :1204-1210
[7]   Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry [J].
Ehrich, M ;
Nelson, MR ;
Stanssens, P ;
Zabeau, M ;
Liloglou, T ;
Xinarianos, G ;
Cantor, CR ;
Field, JK ;
van den Boom, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (44) :15785-15790
[8]   Overexpression of I kappa B alpha without inhibition of NF-κB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells [J].
Emmerich, F ;
Meiser, M ;
Hummel, M ;
Demel, G ;
Foss, HD ;
Jundt, F ;
Mathas, S ;
Krappmann, D ;
Scheidereit, C ;
Stein, H ;
Dorken, B .
BLOOD, 1999, 94 (09) :3129-3134
[9]   Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia [J].
Gebhard, Claudia ;
Schwarzfischer, Lucia ;
Pham, Thu-Hang ;
Schilling, Elmar ;
Klug, Maja ;
Andreesen, Reinhard ;
Rehli, Michael .
CANCER RESEARCH, 2006, 66 (12) :6118-6128
[10]   Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia [J].
Hewamana, Saman ;
Lin, Thet Thet ;
Rowntree, Clare ;
Karunanithi, Kamaraj ;
Pratt, Guy ;
Hills, Robert ;
Fegan, Chris ;
Brennan, Paul ;
Pepper, Chris .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :763-769